PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD).
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD).
PERTH, Australia – In 2017, Australia's Therapeutic Goods Administration (TGA) approved the lowest number of new molecular entities since 2012 – just 34, compared to 42 in 2016 and 45 in 2015.
PERTH, Australia – Allergan plc is acquiring Sydney-based Elastagen Pty Ltd., a private company with a tissue repair platform that complements Allergan's aesthetic and dermatology franchise.
PERTH, Australia – Australian biotech company Patrys Ltd. is developing an antibody that can enter the cell nucleus. If clinical trials go well, it would be a game-changer, because it would mean that intracellular targets could be accessible to antibodies.
PERTH, Australia – Allergan plc is acquiring Sydney-based Elastagen Pty Ltd., a private company with a tissue repair platform that complements Allergan's aesthetic and dermatology franchise.
